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 Axillary lymph node status is one of the most important prognostic 
factors for breast cancer patients ( 1 ). A sentinel lymph node biopsy 
examination is a safe and accurate initial staging method for lymph 
nodes of patients with early-stage breast cancer and has largely 
replaced axillary lymph node dissection as the preferred staging 
method ( 2 ). Selective targeting of the sentinel lymph node with 
enhanced pathological analysis (ie, step sectioning and immuno-
histochemistry) has led to an increased rate of identifying positive 
lymph nodes ( 3 , 4 ). However, the clinical significance of small 
groups of metastatic cells in lymph nodes is unclear. 
 The sixth edition of the Cancer Staging Manual of the 
American Joint Committee on Cancer (AJCC), which was ﬁ rst 
published in 2002, distinguishes between isolated tumor cells 
(clusters with diameters of  ≤ 0.2 mm) and micrometastases (tumor 
cell clusters of >0.2 but  ≤ 2 mm) on the basis of cluster size, reﬂ ect-
ing the increased use of the sentinel lymph node biopsy method 
for lymph node staging. According to the ﬁ rst publication ( 5 ), the 
category no regional lymph node metastases (pN0) was given an 
additional description “i” [pN0(i+)] for metastatic cells visible by 
immunohistochemistry only. That is, pN0(i+) indicated that lymph 
node metastases were not detected on hematoxylin-eosin – stained 
lymph node sections but were detected by immunohistochemistry 
and that each tumor cluster had a diameter of no more than 
0.2 mm. These deﬁ nitions were clariﬁ ed in the 2003 revision ( 6 ), 
so that the i description referred to the presence (i+) or absence 
(i  ) of isolated tumor cells (clusters with diameters of  ≤ 0.2 mm) 
regardless of detection method. These patients have been assigned 
to the N0 group for staging and treatment purposes because 
“the unknown beneﬁ ts of providing treatment for these small 
lesions would not overweigh the morbidity caused by the 
treatment itself” ( 7 ). 
 Although there is agreement that patients whose sentinel lymph 
node contain micro- and/or macrometastases (ie, those in the N1 
category) should be subjected to axillary lymph node dissection, 
controversy exists as to whether there is a beneﬁ t associated with 
axillary lymph node dissection for patients whose sentinel lymph 
node contains isolated tumor cells. Several studies ( 8 – 10 ) report an 
association between the size of metastases in the sentinel lymph 
node and non – sentinel lymph node involvement. Before the intro-
duction of the current deﬁ nition of isolated tumor cells, such groups 
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 Non – Sentinel Lymph Node Metastases Associated With Isolated 
Breast Cancer Cells in the Sentinel Node 
 Carolien H. M.  van Deurzen ,  Maaike  de Boer ,  Evelyn M.  Monninkhof ,  Peter  Bult ,  Elsken  van der Wall ,  Vivianne C. G.  
 Tjan-Heijnen ,  Paul J.  van Diest 
 There are many reports on the frequency of non – sentinel lymph node involvement when isolated tumor cells are found in the 
sentinel node, but results and recommendations for the use of an axillary lymph node dissection differ among studies. This 
systematic review was conducted to give an overview of this issue and to provide recommendations for the use of an axillary 
lymph node dissection in these patients. We searched Medline, Embase, and Cochrane databases from January 1, 2002, through 
November 27, 2007, for articles on patients with invasive breast cancer who had isolated tumor cells in the sentinel lymph node 
(according to the sixth edition of the Cancer Staging Manual of the American Joint Committee on Cancer) and who also under-
went axillary lymph node dissection. Of 411 selected articles, 29 (including 836 patients) were included in this review. These 29 
studies were heterogeneous, reporting a wide range of non – sentinel lymph node involvement (defined as the presence of iso-
lated tumor cells or micro- or macrometastases) associated with isolated tumor cells in the sentinel lymph node, with an overall 
pooled risk for such involvement of 12.3% (95% confidence interval = 9.5% to 15.7%). This pooled risk estimate was marginally 
higher than the risk of a false-negative sentinel lymph node biopsy examination (ie, 7% – 8%) but marginally lower than the risk 
of non – sentinel lymph node metastases in patients with micrometastases (ie, approximately 20%) who are currently eligible for 
an axillary lymph node dissection. Because 36 (64%) of the 56 patients with isolated tumor cells in their sentinel lymph node 
also had non – sentinel lymph node macrometastases, those patients with isolated tumor cells in the sentinel lymph node with-
out other indications for adjuvant systemic therapy might be candidates for axillary lymph node dissection. 
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of metastatic cells were included in the micrometastases category 
(pN1a) and thus usually integrated into the group of metastases 
detected by immunohistochemistry only. A meta-analysis by Cserni 
et al. ( 11 ) reported an overall risk of non – sentinel lymph node 
involvement of 9%, when sentinel lymph node metastases were 
detectable by immunohistochemistry only. Since the introduction 
of the current deﬁ nition of isolated tumor cells, a growing number 
of studies ( 12 – 14 ) have assessed the detection rate of non – sentinel 
lymph node metastases in patients who have isolated tumor cells in 
their sentinel lymph node, but the results and recommendations 
from these studies for the use of axillary lymph node dissection 
have varied. This systematic review was conducted to give an over-
view of these results and provide recommendations regarding the 
role of an axillary lymph node dissection in patients with isolated 
tumor cells in their sentinel lymph node. 
 Patients and Methods 
 Literature Search Strategy 
 The electronic databases of Medline, Embase, and Cochrane were 
searched from January 1, 2002, through November 27, 2007, by 
use of variations of free text and controlled terms for breast cancer 
and sentinel lymph node and non – sentinel lymph node involve-
ment. The year 2002 was selected because the sixth edition of the 
AJCC Cancer Staging Manual was published this year. Articles 
published in English, German, French, or Dutch were considered. 
Two reviewers (C. H. M. van Deurzen and M. de Boer) indepen-
dently evaluated titles and abstracts of the identified papers. The 
full text of potentially relevant articles was then reviewed. 
 Study Inclusion Criteria 
 To be included in this review, studies had to meet three inclusion 
criteria. First, patients had to have invasive breast cancer. Second, 
patients must have had a sentinel lymph node biopsy procedure 
followed by an axillary lymph node dissection. Third, isolated 
tumor cells had to be classified according to the sixth edition of the 
AJCC Cancer Staging Manual (tumor cell clusters with a diameter 
of  ≤ 0.2 mm). Studies were excluded that reported on a sentinel 
lymph node biopsy procedure after neoadjuvant chemotherapy, 
microinvasive breast cancer, or sentinel lymph node tumor depos-
its without size definition according to the sixth edition of the 
AJCC Cancer Staging Manual. 
 Data Extraction and Statistical Analysis 
 Data extraction was carried out independently by two reviewers 
(C. H. M. van Deurzen and M. de Boer). Any disagreement was 
resolved by consensus. Data were extracted by use of standardized 
data extraction forms. We documented sample size, inclusion and 
exclusion criteria, primary tumor characteristics, definition of iso-
lated tumor cells, sentinel lymph node biopsy protocol (blue dye 
and/or colloid and the injection site), processing methods for sen-
tinel lymph nodes and non – sentinel lymph nodes, level of axillary 
lymph node dissection, and number of patients with isolated tumor 
cells in their sentinel lymph node and with non – sentinel lymph 
node metastases. The AJCC classification of non – sentinel lymph 
node metastases, including isolated tumor cells (cell clusters with 
diameters of  ≤ 0.2 mm), micrometastases (tumor cell clusters >0.2 
but  ≤ 2 mm), and macrometastases (tumor cell clusters >2 mm), 
was also recorded. In some instances, corresponding authors were 
contacted for additional information. 
 We calculated 95% conﬁ dence intervals (CIs) for the risks of 
non – sentinel lymph node involvement within the studies by use of 
the Rothman spreadsheet ( 15 ). A random-effects meta-analysis 
with an exact likelihood approach was used to calculate pooled risk 
estimates of non – sentinel lymph node involvement and 95% con-
ﬁ dence intervals ( 16 ). The extent to which one or more study 
characteristics explained between-study heterogeneity was explored 
by use of metaregression analysis ( 17 ). The following variables 
were considered: the number of levels of the sentinel lymph node 
or non – sentinel lymph nodes that were stained with hematoxylin – 
eosin and/or by immunohistochemistry. Systematic differences 
between small and large studies were assessed by use of a funnel 
plot ( 18 ). Statistical analyses were performed with SAS version 9.1. 
All statistical tests were two-sided. 
 Results 
 The initial electronic search identified 411 potentially relevant 
articles of which we screened the title and abstract. After that 
screening, the full texts of 144 articles were obtained. After full text 
review and exclusion of overlapping series, 29 articles that met the 
inclusion and exclusion criteria for this study were identified and 
used for data extraction. The main characteristics and results of 
these studies are summarized in  Table 1 . These studies were het-
erogeneous regarding study design, size, inclusion criteria for 
sentinel lymph node biopsy examination, sentinel lymph node 
biopsy technique, and histopathological work-up. Overall, these 
29 studies included 836 patients, of whom 108 had non – sentinel 
lymph node involvement. 
 Sentinel lymph nodes were usually identiﬁ ed by use of blue dye 
in combination with radioactive colloid that was injected peritu-
morally. The detection rate of non – sentinel lymph node metasta-
ses ranged from 0% through 27%, with a pooled risk for 
non – sentinel lymph node metastases of 12.3% (95% CI = 9.5% to 
15.7%). Data on the size of non – sentinel lymph node metastases 
and whether such metastases were considered in the treatment of 
the patient were scarce. In 10 of the 17 studies with non – sentinel 
lymph node involvement, information was available on the type of 
metastases that was classiﬁ ed according to the sixth edition of the 
AJCC Cancer Staging Manual. The pooled risk of non – sentinel 
lymph node macrometastases, after a positive sentinel lymph node 
was found, in these studies was 63.5% (95% CI = 38.1% to 83.1%). 
The funnel plot did not indicate systematic differences in the 
frequency of non – sentinel lymph node metastases between large 
studies and smaller studies ( Figure 1 ). However, the range of non – 
sentinel lymph node metastases (5% – 19%) in larger studies (ie, 
those with >30 patients) was smaller than the range (0% – 27%) in 
smaller studies (ie, those with <30 patients). 
 Metaregression analysis revealed that the number of assessed 
levels of the sentinel lymph node or non – sentinel lymph nodes 
stained with hematoxylin – eosin and/or immunohistochemistry (ie, 
deﬁ ned as the number of lymph node sections assessed by patho-
logical analysis) did not contribute substantially to between-study 
heterogeneity in non – sentinel lymph node involvement. Because 
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the included articles did not further specify clinicopathologic fea-
tures of patients with a sentinel lymph node containing isolated 
tumor cells, we could not formulate recommendations for the use 
of axillary lymph node dissection for patients with sentinel lymph 
node involvement. 
 Discussion 
 In this systematic literature review, we have summarized the avail-
able studies reporting on the risk of non – sentinel lymph node 
involvement after isolated tumor cells were found in the sentinel 
lymph node. The overall incidence of non – sentinel lymph node 
involvement ranged from 0% to 27%. The pooled overall risk of 
non – sentinel lymph node involvement was 12.3% (95% CI = 9.5% 
to 15.7%), and 63.5% (95% CI = 38.1% to 83.1%) of non – sentinel 
lymph node metastases were macrometastases. 
 This study had several limitations. First, the studies included in 
the analysis did not specify the clinicopathologic details of those 
patients with isolated tumor cells and non – sentinel lymph node 
involvement. Therefore, with the currently available data, we can-
not generate recommendations for the use of an axillary lymph node 
dissection in subgroups of patients with isolated tumor cells in the 
sentinel lymph node. Second, many of the included studies in this 
analysis did not further classify non – sentinel lymph node metastases 
(ie, isolated tumor cells or micro- or macrometastases). Therefore, 
the risk calculation for macrometastases in the non – sentinel lymph 
node was based on a relatively small number of studies. 
 The large range of non – sentinel lymph node involvement may 
stem partially from differences in study design, inclusion criteria 
for a sentinel lymph node biopsy procedure in this study, sentinel 
lymph node biopsy technique, and/or the processing and interpre-
tation of metastatic deposits. First, included studies may be lim-
ited, in part, by their retrospective design because not all patients 
with a sentinel lymph node containing isolated tumor cells may 
have undergone an axillary lymph node dissection. The subgroup 
of patients with a sentinel lymph node containing isolated tumor 
cells who underwent an axillary lymph node dissection may have 
been selected because they appeared to have more aggressive pri-
mary disease. Second, exclusion criteria for sentinel lymph node 
biopsy procedure differed by the largest included clinical tumor 
diameter (ie, 3 or 5 cm). Third, the sentinel lymph node biopsy 
protocol differed by the type of substance injected (colloid and/or 
blue dye) and injection site (subdermal, peritumoral, or periareo-
lar), although the inﬂ uence of these variables was probably mini-
mal. Fourth, the included studies used different protocols for 
sentinel lymph node and non – sentinel lymph node analyses, with 
a wide range in the number of slides, depth of section intervals, and 
use of immunohistochemistry. The detection rate of isolated 
tumor cells in the sentinel lymph node decreased with less exten-
sive pathological work-up (ie, analysis of a low number of lymph 
node sections or a lack of routine use of immunohistochemistry) 
and some sentinel lymph nodes classiﬁ ed as having isolated tumor 
cells may, in fact, have had micrometastases at deeper levels; 
these variations would be expected to affect the risk and type of 
non – sentinel lymph node involvement observed. The risk of non – 
sentinel lymph node involvement was affected by the size of 
sentinel lymph node metastases; the larger the metastasis in the 
sentinel lymph node, the higher the risk of non – sentinel lymph 
node involvement. Because pathological sampling involves assess-
ment of a fraction of the lymph node volume only, there may be 
discordance between the detected sentinel lymph node metastatic 
size and its true size. In this systematic review, however, the num-
ber of assessed levels (deﬁ ned as the number of lymph node 
sections assessed by pathological analysis) of the sentinel lymph 
node and non – sentinel lymph nodes stained with hematoxylin – eosin 
and by use of immunohistochemistry could not explain the 
between-study heterogeneity. Non – sentinel lymph nodes are 
generally examined less extensively without the routine use of 
immunohistochemistry, and this practice may underestimate the 
actual risk of small non – sentinel lymph node metastases after 
isolated tumor cells are found in the sentinel lymph node. The use 
of immunohistochemistry in the work-up of non – sentinel lymph 
nodes increases the detection rate of (small) non – sentinel lymph 
node metastases ( 46 ), so omitting immunohistochemistry for 
non – sentinel lymph nodes is likely to result in a relatively high 
percentage of non – sentinel lymph node macrometastases. However, 
Changsri et al. ( 24 ) reported only on isolated tumor cells in 
non – sentinel lymph nodes, by examining a single section of the 
non – sentinel lymph node by hematoxylin – eosin only. In their 
study, all patients with isolated tumor cells in their sentinel lymph 
node also had isolated tumor cells in their non – sentinel lymph 
nodes. They concluded that additional metastases in non – sentinel 
lymph nodes of patients with isolated tumor cells in the sentinel 
lymph node should also be of a small size, which is in contrast with 
the results of this systematic review. Finally, the heterogeneity of 
the results of these studies could be due to various interpretations 
of the current deﬁ nition of isolated tumor cells, which do not 
permit a reproducible distinction between micrometastases and 
isolated tumor cell ( 47 – 49 ). 
 In, to our knowledge, the largest study of isolated tumor cells 
in the sentinel lymph node followed by axillary lymph node 
dissection (n = 187), Houvenaeghel et al. ( 12 ) reported a 16% rate 
of non – sentinel lymph nodes involvement. This retrospective 
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 Figure 1 .  Funnel plot. The 29 studies on non – sentinel lymph node 
involvement associated with isolated breast cancer cells in the sentinel 
node were analyzed (see  Table 1 for these studies). The study size 
(deﬁ ned as the number of patients included with isolated tumor cells in 
the sentinel node and who also underwent axillary lymph node dissec-
tion) is plotted on the horizontal axis, and the percentage of these 
patients with non – sentinel lymph node metastases is plotted on the 
vertical axis. Each point represents a published study. 
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multicenter study reported no statistically signiﬁ cant difference in 
the risk of non – sentinel lymph node involvement between sentinel 
lymph nodes that contained isolated tumor cells (16%) and those 
that contained micrometastases (14.3%). However, they reported 
a 9.9% detection rate of non – sentinel lymph node involvement in 
a large group (n = 212) of sentinel lymph nodes containing micro-
metastases that had an unknown diameter (which also included 
isolated tumor cells). No mention was made as to whether addi-
tional non – sentinel lymph node metastases were associated with 
therapeutic decision making. They found that the only proposed 
subgroups of patients for whom axillary lymph node dissection 
could be avoided were patients with a small primary tumor (pT1a 
or pT1b) or with pT1 tubular, colloidal, or medullary tumors, with 
a risk for non – sentinel lymph node involvement of 5% or less. 
 In the second largest study (n = 116), Viale et al. ( 14 ) reported 
non – sentinel lymph node involvement in 15% of patients whose 
sentinel lymph node contained isolated tumor cells; this non – sen-
tinel lymph node involvement was further classiﬁ ed as isolated 
tumor cells (6%) or micrometastasis (18%) or macrometastasis 
(76%). They included clinically lymph node – negative patients 
with early breast cancer (breast tumor diameter of  ≤ 3 cm). The 
6.7% difference in the detection rate of non – sentinel lymph node 
involvement between sentinel lymph nodes containing isolated 
tumor cells (14.7%) and micrometastases (21.4%) was not statisti-
cally signiﬁ cant. The identiﬁ cation of these non – sentinel lymph 
node metastases, which were mostly macrometastases, affected 
further systemic therapy in most patients whose sentinel lymph 
node contained isolated tumor cells or micrometastases. They 
concluded that the current categories, which were introduced by 
the sixth edition of the AJCC Cancer Staging Manual, cannot 
safely be adopted to tailor axillary surgical treatment for patients 
undergoing a sentinel lymph node biopsy procedure. A predictive 
model that was based on features associated with non – sentinel 
lymph node involvement could not identify a subgroup of patients 
with less than 13% non – sentinel lymph node involvement. From 
these results, Viale et al. recommended axillary lymph node dissec-
tion if there was any evidence of sentinel lymph node involvement 
in all settings except clinical trials. However, it must be empha-
sized that their assessment of the sentinel lymph node (by frozen 
sections and without routine immunohistochemistry) was likely to 
have decreased the detection rate of isolated tumor cells in the 
sentinel lymph node, which would, therefore, affect the detectable 
rate of non – sentinel lymph node involvement. 
 The decision of whether or not to proceed with an axillary 
lymph node dissection after ﬁ nding isolated tumor cells in the 
sentinel lymph node was based on the risk of the procedure itself 
and on the risk and clinical signiﬁ cance of leaving residual disease 
in the axilla. The size of metastatic tumor material in the sentinel 
lymph node was one of the strongest predictors of non – sentinel 
lymph node involvement, although other characteristics (increased 
tumor size, more than one positive sentinel lymph node, and lym-
phovascular invasion in the primary tumor) also have statistically 
signiﬁ cant predictive value ( 50 ). From the studies included in this 
systematic review, the pooled risk of non – sentinel lymph node 
involvement among patients whose sentinel lymph node contained 
isolated tumor cells was approximately 12.3%, which is only mar-
ginally lower than the risk of non – sentinel lymph node involve-
ment in patients with sentinel lymph node micrometastases (ie, 
approximately 20%) ( 11 , 14 , 51 ) who are currently eligible for axil-
lary lymph node dissection. It could therefore be argued that 
patients whose sentinel lymph node contained isolated tumor cells 
should also undergo an axillary lymph node dissection. However, 
this risk of non – sentinel lymph node involvement in patients with 
isolated tumor cells in the sentinel node is only marginally higher 
than the risk of a false-negative sentinel lymph node biopsy exami-
nation (7% – 8%) ( 52 , 53 ), and we do not advocate axillary lymph 
node dissection for patients with sentinel lymph node – negative 
breast cancer. In addition, the clinical signiﬁ cance of residual axil-
lary disease when axillary lymph node dissection is not performed 
is unclear. The risk of axillary recurrence if residual disease is pres-
ent is probably low, and whether axillary lymph node dissection 
provides a survival beneﬁ t for sentinel lymph node – positive 
patients is not clear. Several studies ( 54 – 56 ), although limited by 
size and follow-up time, reported a very low rate of axillary recur-
rence in patients with a positive sentinel lymph node who did not 
undergo axillary lymph node dissection. This result may be due to 
selection of low-risk patients, limited outgrowth potential of 
residual tumor, or the effects of local radiotherapy. Furthermore, 
most breast cancer patients receive adjuvant systemic therapy 
when their primary tumor has unfavorable characteristics, and such 
therapy may also eradicate residual lymph node metastases. With 
regard to local control, a wait-and-see policy may therefore be 
acceptable when the sentinel lymph node contains isolated tumor 
cells. However, a substantial proportion (approximately 64%) of 
non – sentinel lymph node metastases identiﬁ ed in patients with 
sentinel lymph nodes containing isolated tumor cells are macro-
metastases, which require adjuvant systemic therapy. Failure to 
detect these non – sentinel lymph node macrometastases by omit-
ting axillary lymph node dissection could thus result in undertreat-
ment of those patients whose sentinel lymph node contains isolated 
tumor cells but whose primary tumor characteristics do not indi-
cate the need for adjuvant therapy. 
 In conclusion, results on isolated tumor cells in the sentinel 
lymph node are somewhat controversial, and there is still doubt 
about the need for axillary lymph node dissection after ﬁ nding 
isolated tumor cells in the sentinel lymph node. A wait-and-see 
policy is probably acceptable for most patients whose sentinel 
lymph node contains isolated tumor cells. However, for patients 
with a sentinel lymph node that contains isolated tumor cells, 
axillary lymph node dissection could be used if the indication for 
adjuvant systemic therapy is inﬂ uenced by ﬁ nding macrometasta-
ses on full lymph node staging. In this respect, the risk of non – 
sentinel lymph node involvement also depends on other risk 
factors (ie, primary tumor size and the presence of lymphovascu-
lar invasion). Molecular proﬁ ling of metastatic deposits, which 
could be distinct from the primary tumor ( 57 ), could be used to 
further select patients who might beneﬁ t from axillary lymph 
node dissection. Findings from large ongoing clinical trials, such 
as the International Breast Cancer Study Group 2301 trial, which 
has randomly assigned sentinel lymph node – positive patients to 
axillary lymph node dissection or surveillance, may provide 
greater clinical evidence regarding policies on axillary lymph 
node dissection after the identiﬁ cation of a positive sentinel 
lymph node. 
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